MX2023007062A - Metodos de tratamiento de la diabetes. - Google Patents

Metodos de tratamiento de la diabetes.

Info

Publication number
MX2023007062A
MX2023007062A MX2023007062A MX2023007062A MX2023007062A MX 2023007062 A MX2023007062 A MX 2023007062A MX 2023007062 A MX2023007062 A MX 2023007062A MX 2023007062 A MX2023007062 A MX 2023007062A MX 2023007062 A MX2023007062 A MX 2023007062A
Authority
MX
Mexico
Prior art keywords
methods
treating diabetes
weekly
dosing
bif
Prior art date
Application number
MX2023007062A
Other languages
English (en)
Inventor
Molly Corbett Carr
A/K/A/ Jenny Y Chien Yueh - Ling Chien
Emmanuel Chigutsa
Parag Garhyan
Axel Richard Karl - August Haupt
Cheng Cai Tang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2023007062A publication Critical patent/MX2023007062A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/3159—Dose expelling manners
    • A61M5/31591—Single dose, i.e. individually set dose administered only once from the same medicament reservoir, e.g. including single stroke limiting means

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

En el presente documento se describen dosis fijas y regímenes de dosificación para agonistas de receptor de insulina de acción prolongada adecuados para dosificación una vez por semana, tales como insulina basal-Fc (BIF) semanal.
MX2023007062A 2020-12-14 2021-12-14 Metodos de tratamiento de la diabetes. MX2023007062A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063125165P 2020-12-14 2020-12-14
PCT/US2021/063235 WO2022132712A1 (en) 2020-12-14 2021-12-14 Methods of treating diabetes

Publications (1)

Publication Number Publication Date
MX2023007062A true MX2023007062A (es) 2023-06-23

Family

ID=79287778

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023007062A MX2023007062A (es) 2020-12-14 2021-12-14 Metodos de tratamiento de la diabetes.
MX2023007064A MX2023007064A (es) 2020-12-14 2021-12-14 Metodos para tratar la diabetes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023007064A MX2023007064A (es) 2020-12-14 2021-12-14 Metodos para tratar la diabetes.

Country Status (11)

Country Link
US (2) US20240050532A1 (es)
EP (2) EP4259185A1 (es)
JP (2) JP2023554358A (es)
KR (2) KR20230118936A (es)
CN (2) CN116710119A (es)
AU (2) AU2021400816A1 (es)
CA (2) CA3199645A1 (es)
IL (2) IL303630A (es)
MX (2) MX2023007062A (es)
TW (2) TW202237174A (es)
WO (2) WO2022132712A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024059480A2 (en) * 2022-09-12 2024-03-21 Eli Lilly And Company A gip/glp1 for use in therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117742C2 (uk) 2010-03-01 2018-09-25 Елі Ліллі Енд Компані Пристрій для автоматичного виконання ін'єкції з механізмом затримки, який включає в себе пересувальний елемент подвійного призначення
EP2869830B1 (en) 2012-07-09 2016-10-12 Novo Nordisk A/S Novel use of insulin derivatives
WO2016001185A1 (en) 2014-07-02 2016-01-07 Novo Nordisk A/S Dosage regimen for the treatment of diabetes
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
LT3892628T (lt) * 2018-06-29 2022-12-12 Akston Biosciences Corporation Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
EP3863680A1 (en) * 2018-10-10 2021-08-18 Novo Nordisk A/S Oligomer extended insulin-fc conjugates and their medical use

Also Published As

Publication number Publication date
JP2023554358A (ja) 2023-12-27
IL303630A (en) 2023-08-01
CN116710119A (zh) 2023-09-05
AU2021400816A1 (en) 2023-06-22
EP4259185A1 (en) 2023-10-18
JP2024502720A (ja) 2024-01-23
US20240082363A1 (en) 2024-03-14
CA3202345A1 (en) 2022-06-23
TW202237175A (zh) 2022-10-01
TW202237174A (zh) 2022-10-01
MX2023007064A (es) 2023-07-31
KR20230118648A (ko) 2023-08-11
EP4259186A1 (en) 2023-10-18
WO2022132712A1 (en) 2022-06-23
IL303631A (en) 2023-08-01
US20240050532A1 (en) 2024-02-15
CA3199645A1 (en) 2022-06-23
AU2021401635A1 (en) 2023-06-22
KR20230118936A (ko) 2023-08-14
WO2022132709A1 (en) 2022-06-23
CN116723852A (zh) 2023-09-08

Similar Documents

Publication Publication Date Title
MX2023007062A (es) Metodos de tratamiento de la diabetes.
Xu et al. Anti-gastric cancer effect of melatonin and Bcl-2, Bax, p21 and p53 expression changes
Augustin et al. Effect of retinal coagulation status on oxidative metabolite and VEGF in 208 patients with proliferative diabetic retinopathy
Richter et al. The prognostic significance of epidermal growth factor receptor expression in patients with anal carcinoma.
Li et al. Summary and expectation of the role of GnRHa in the treatment of breast cancer
Williams et al. Cytokine regulation of hematopoietic stem cells.
Smol'iakova et al. Evaluation of the linearity of pharmacokinetics of the phenolic antioxidant 4-methyl-2, 6-diisobornylphenol upon intragastric administration
Arribas Del Amo et al. Direct-to-implant breast reconstruction after neoadjuvant chemotherapy: A safe option?
Matsubara et al. Impact of HER2, EGFR, IGF-1R, and VEGFR expressions on the outcome of chemotherapy for advanced gastric cancer
Zu et al. The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Ruan et al. Outcome of childhood high-risk acute lymphoblastic leukemia treated with the ALL-BFM 95 protocol
Richter et al. Docetaxel-Cabazitaxel-Enzalutamide Versus Docetaxel-Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Sedakov et al. Combined treatment for unresectable head and neck tumors using radiotherapy in combination with regional chemotherapy.
Xuan et al. Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation
Ryoken Prospective analysis of adverse reactions with long-term levofloxacin use
Brančíková et al. A case report: patient with advanced ovarial tumour and supporting care
Růcková et al. Hsp90--a target for anticancer therapy
Žďarská et al. The PROROK project results after 6 months of intervention (Prospective observation project focusing on the relevance of the difference between fasting blood glucose levels and postprandial blood glucose for estimation of success of type 2 diabetes therapy)
Mo et al. Phosphodiesterase type 5 inhibitors for premature ejaculation: advances in studies
JC et al. Immunotherapy in Combination with Chemotherapy for Triple-Negative Breast Cancer.
Komoto et al. Successful Multimodality Treatment Including Three-Stage Operation for Esophageal Cancer with Esophagorespiratory Fistula-A Case Report
Ogura Progress in therapeutic strategy for malignant lymphoma
Mochinaga et al. Efficacy of aprepitant for quality of life of outpatients receiving moderately emetogenic chemotherapy
Zhang et al. Characteristics of boningmycin induced cellular senescence of human tumor cells
Di Raimondo et al. Management of multiple myeloma